Fleetwood: A buy after the bust?
Fleetwood's dramatic decline is either the inevitable end of a frothy boom or an opportunity for the patient. Gaurav Sodhi decides.
Turn off the TELYS4
With Seven Group's deteriorating finances and the seemingly distant prospect of redemption, we're tuning out of these income securities.
Abacus: Interim result 2014 and SPP
Abacus Property delivered a sound interim result, but the office market is starting to look shaky.
Metcash model is fundamentally flawed
This retailer's latest strategic review highlights its problems, but the suggested solutions are unlikely to fix them.
M2: Interim result 2014
The squabbling continues over the NBN, but M2 should be able to earn its crust whoever's allowed to build what.
SomnoMed: Interim result 2014
Unit sales and revenues are growing strongly at SomnoMed, although higher profits will have to wait as the company continues to invest.
Sirtex targets growing market
This developer of treatments for liver cancer has been an excellent performer, but what's it really worth?
Caltex: Result 2013
Margins from Caltex's refining business might swing wildly but its retail business continues to march higher.
Nanosonics builds a better mousetrap
Nanosonics' ultrasound probe sterilisers are finally flying off the shelves, but sales are just warming up.
Alumina: Result 2013
You wouldn't know it from its latest result, but our investment thesis for this part-owner of the world's largest producer of alumina is on track.
Ramsay Health Care: Interim result 2014
Ramsay has reported another impressive result, but it needs to with the share price at current levels.
Westfield: Result 2013
The divide between Westfield's international and Australian operations continues to grow, as Graham Witcomb explains.
Tap Oil: Result 2013
Once again, Tap Oil has produced zero oil and gas and limited cash flow, but that is about to change.
HPI: beer we go again
ALE Group is superior to rival pub landlord Hotel Property Investments in almost every respect – except the one that matters most.
Call 1300 880 160
Start a chat
Schedule a call
